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Background: Peritoneal carcinomatosis is life-threatening without cytoreductive surgery (CRS) and perioperative
intraperitoneal chemotherapy (PIC). Only a few studies in the literature addressed the relationship between age
and outcomes of peritonectomy. This study was designed to review the clinical outcomes in elderly patients who
underwent CRS and PIC.
Methods: This is a retrospective study of prospectively collected data of 611 consecutive patients with peritoneal
carcinomatosis who underwent CRS and PIC by the same surgical team at St George Hospital in Sydney, Australia,
between January 1996 and December 2013. Patients were divided into two groups; group 1 (<65 years old, n = 487)
and group 2 (≥ 65 years old, n = 124). Subgroup analysis was performed in patients who were ≥75 years old (n = 20). A
significant difference was defined as p < 0.05.
Results: There was no significant statistical difference in terms of mean total hospital stay, intensive care unit stay, high
dependency unit stay and complication rates. Postoperative mortality was 2 and 3 % in groups 1 and 2, respectively.
Overall survival did not reach a statistical significance between the two groups. In subgroup analysis, patients showed
similar morbidity results to patients who were <65 years old.
Conclusions: CRS and PIC can be safely done in the elderly. Age alone should not be the single exclusion criterion but
rather taken into consideration along with other factors to determine the suitability of elderly patients.
Keywords: Cytoreductive surgery, Peritonectomy, Peritoneal carcinomatosis, ElderlyBackground
Peritoneal carcinomatosis is considered as a fatal condi-
tion without surgical and intraperitoneal chemotherapy
interventions [1, 2]. Common malignancies involved in-
clude appendiceal cancer, colorectal cancer (CRC), meso-
thelioma, gastric cancer and ovarian cancer. Peritoneal
carcinomatosis is currently treated with a combination of
cytoreductive surgery (CRS) and perioperative intraperito-
neal chemotherapy (PIC) by using the coliseum technique
developed by Sugarbaker in the 1990s [3, 4]. PIC includes
hyperthermic intraperitoneal chemotherapy (HIPEC) after* Correspondence: david.morris@unsw.edu.au
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(http://creativecommons.org/publicdomain/zeCRS, and also, normothermic intraperitoneal chemother-
apy is used by some units in the postoperative period
(EPIC) [5]. A recent systematic review done by Chua et al.
has shown an optimal morbidity rate ranging from 12 to
52 % and a mortality rate ranging 0.9 and 5.8 % [6]. A con-
siderable number of patients with peritoneal carcinoma-
tosis are aged 60 or older and are more commonly
associated with comorbidities due to their age [7, 8]. Thus,
whether the elderly can tolerate such an invasive surgery
presents a challenge for healthcare professionals. A few
studies have previously investigated the relationship be-
tween age and the outcome of peritonectomy [7–9]. How-
ever, these studies were limited by their small sample size.
The aim of this study was to review the short-term
clinical outcomes and long-term survival in elderly pa-
tients who underwent CRS and PIC.e is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Settings
This is a retrospective study of prospectively collected
data of 611 consecutive patients with peritoneal carcin-
omatosis who underwent CRS and PIC by the same sur-
gical team at St George Hospital in Sydney, Australia,
between January 1996 and December 2013. All the clin-
ical and treatment-related data were collected and entered
into a computerised database in order to evaluate the peri-
operative outcomes of patients with peritoneal surface
malignancy. A signed informed consent was obtained
from all patients. This research was ethically approved by
the Human Research Ethics Committee at South Eastern
Sydney Local Health District, NSW, Australia.
Patients
All patients were managed by a standard treatment
protocol combining CRS and PIC. Suitability to undergo
CRS and PIC was evaluated during a regular weekly
meeting attended by a multidisciplinary team including
surgical oncologists, medical oncologists, radiologists,
cancer care nurses and research staff. Selection criteria
in our centre include (1) proven peritoneal disease; (2)
no extra-peritoneal evidence of disease on preoperative
evaluation including abdominal and chest computed
tomography (CT), CT-angiogram of the liver and posi-
tron emission tomography (PET) scan; (3) able to give
adequate informed consent; (4) performance status
(World Health Organization performance status ≤2);
(5) no severe co-existent visceral disease; (6) adequate
renal, hepatic and haematological reserve; (7) accept-
able intra-operative Peritoneal Cancer Index (PCI ≤ 15
or maximum of four liver metastases and PCI ≤ 10 for
patients with CRC; PCI < 10 for patients with gastric
cancer; no PCI limit for appendiceal cancer, peritoneal
mesothelioma, pseudomyxoma peritonei (PMP) and
ovarian cancer); and (8) appropriate histological sub-
type for given tumour type (exclude those with un-
favourable subtypes with a very high PCI, e.g. mucinous
adenocarcinomas with signet ring differentiation and
sarcomatoid-variant peritoneal mesothelioma).
In this study, 611 patients were divided into two
groups. Group 1 included patients who were less than
65 years old at the time of surgery (n = 487). Group 2 in-
cluded patients who were 65 years of age or older at the
time of surgery (n = 124). A subgroup analysis was per-
formed for patients who are 75 years of age or older at
the time of surgery.
Preoperative management
All patients underwent standard preoperative investiga-
tions which included physical examination; tumour
markers; double contrast-enhanced CT scans of the
chest, abdomen and pelvis; and CT-angiogram of theliver with PMP and CRC. PET scan was performed in
patients with appendiceal adenocarcinoma, CRC and
mesothelioma.
CRS
An initial assessment of the volume and extent of dis-
ease was recorded using the PCI, as described by Jacquet
and Sugarbaker [10]. This assessment combines thick-
ness of lesion size (LS) (LS 0: no macroscopic tumour;
LS 1: tumour <0.5 cm; LS 2: tumour 0.5–5 cm; and LS3:
tumour >5 cm) with tumour distribution (abdominopel-
vic region 0–12) to quantify the extent of disease as a
numerical score (PCI 0–39). CRS was performed using
Sugarbaker’s technique [11]. The aim of CRS was to
remove all macroscopic intraperitoneal and visceral
tumour deposits.
All sites and volumes of residual disease following
CRS were recorded prospectively using the completeness
of cytoreductive (CC) score (CC0—no macroscopic re-
sidual cancer remained; CC1—no nodule >2.5 mm in
diameter remained; CC2—nodules between 2.5 mm and
2.5 cm in diameter remained; CC3—nodules >2.5 cm in
diameter remained) [10]. Perioperative complications in
all patients were graded I to IV with increasing severity
based on the Clavien-Dindo classification of surgical
complications (grade I: no treatment; grade II: medica-
tions only; grade III: surgical, endoscopic or radiological
intervention; grade IV: life-threatening complications re-
quiring intensive care unit (ICU) admission) [12].
HIPEC
After CRS, but prior to intestinal anastomosis or repair
of seromuscular tears, HIPEC was performed by installa-
tion of a heated chemoperfusate into the abdomen using
the coliseum technique at approximately 42 °C for 30 or
90 min during CRS, depending on tumour types. For
PMP, mitomycin C (12.5 mg/m2 over 90 mins) was used.
For peritoneal mesothelioma, cisplatin (100 mg/m2) and
mitomycin (12.5 mg/m2) in 1000 ml normal saline were
given over 90 min. For appendiceal adenocarcinoma and
CRC, oxaliplatin 350 mg/m2 in 500 ml of 5 % dextrose
was given over 30 mins.
EPIC
The criteria for EPIC include absence of leakage of the
intraperitoneal chemotherapy system, absence of major
organ failure and the ability of the patient to tolerate
increased intra-abdominal fluid volume and intra-
abdominal pressure with adequate urine output. EPIC
was withheld if patients were haemodynamically un-
stable or experienced early perioperative complications.
The sump drains were clamped during the EPIC infu-
sion via the peritoneal catheter port. EPIC was only of-
fered to patients with PMP. No EPIC was offered to
Table 1 Background characteristics of patients in group 1 and
group 2
Group 1
(< 65 years old)
Group 2
(≥ 65 years old)
p
Total n = 611
Number n (%) 487 (79.7) 124 (20.3)
Gender n (%) 0.028
Male 198 (40.7) 64 (51.6)
Female 289 (59.3) 60 (48.4)
Age mean (range) 48.4 (14–64) 69.9 (65–85)
Year of operation n (%) 0.235
1996–2002 30 (6.2) 3 (2.4)
2003–2007 126 (25.9) 31 (25.0)
2008–2013 331 (68.0) 90 (72.6)
Diagnosis n (%) 0.118
CRC (n = 184) 137 (28.1) 47 (37.9)
PMP (n = 157) 124 (25.5) 33 (26.6)
Mesothelioma (n = 53) 47 (9.7) 6 (4.8)
Appendiceal cancer (n = 137) 111 (22.8) 26 (21.0)
Others (n = 80) 68 (14.0) 12 (9.7)
HIPEC n (%) 424 (87.1) 95 (76.6) 0.004
EPIC n (%) 237 (48.8) 60 (48.4)
PCI mean (SD) 18.4 (11.2) 16.5 (1.7) 0.095
CC n (%) 0.264
0 394 (81.7) 95 (77.2)
1 75 (15.6) 22 (17.9)
2 9 (1.9) 6 (4.9)
3 4 (0.8) 0 (0)
Transfusion mean (SD) 6.3 (7.8) 4.8 (6.5) 0.048
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5-fluorouracil 650 mg/m2 IP combined with 50 mEq
sodium bicarbonate was administered from days 2 to 6. A
total of five cycles were given. Normally, EPIC was
administered either in the ICU or high dependency unit
(HDU). The intraperitoneal chemotherapy was allowed to
dwell for 23 h before it was removed by closed suction
drains over the course of 1 h. The next installation was
commenced once the abdomen was cleared of fluid as
completely as possible.
Statistical analysis
All statistical analyses were performed using IBM SPSS
for Windows version 22. Comparison of normally dis-
tributed variables was performed using analysis of vari-
ance (one-way ANOVA) test. Categorical variables were
analysed using the chi-square test or Fisher’s exact test
where appropriate. Perioperative morbidity and mortal-
ity were the primary outcomes of this study. Hospital
mortality was defined as any death that occurred during
the same hospital admission for CRS. Median survival
was calculated based on the date of death or last follow-
up in the unit of months. Survival analysis was performed
using the Kaplan-Meier curves and log-rank test for com-




Six hundred eleven patients underwent CRS combined with
PIC. The mean age of the study group was 52.8 years old
(standard deviation (SD) = 13.1, median = 54.0, range = 71).
There were 262 males (42.9 %) and 349 females
(57.1 %). The diagnoses included CRC (n = 184, 30.1 %),
PMP (n = 157, 25.7 %), mesothelioma (n = 53, 8.7 %),
appendiceal cancer (n = 137, 22.4 %) and other cancers
(n = 80, 13.1 %).
Patients’ background characteristics were summarised
in Table 1. In the elderly group, the mean PCI was 16.5
(SD = 11.7) and a complete cytoreduction (CC0) was
achieved in 77 % patients. The younger group had a
mean PCI of 18.4 (SD = 11.2), and a CC0 was achieved
in 81 % of young patients. There was no significant
statistical difference in terms of year of operation,
diagnosis, mean PCI and CC score between the two
groups (p = 0.235, 0.118, 0.095 and 0.264, respectively)
(Table 1). However, patients who were 65 years of
age or older required significantly lower mean trans-
fusion units (4.8, SD = 6.5) as compared with patients
aged less than 65 years old (6.3, SD = 7.8) (p = 0.048).
Perioperative mortality results
Table 2 demonstrates the morbidity and mortality rates.
The total hospital mortality was 2.3 % (n = 14). Thehospital mortality rate in the patients aged older than
70 years old was 3 %, which is higher than that of the
other younger patients. Nevertheless, such a difference
in terms of mortality between the groups did not reach a
statistical significance (p = 0.607).Perioperative morbidity results
The mean of total hospital stay was 29 days (SD = 26,
median = 22, range = 301). There was no significant dif-
ference among the three groups in terms of total hos-
pital stay, ICU stay and HDU stay (p = 0.607, 0.629 and
0.831, respectively) (Table 2).
Twenty percent of the elderly patients did not experi-
ence any complication, whereas only 18 % of patients in
the younger group experienced no complications. The
most common complications included intra-abdominal
collection (n = 230, 37.6 %), infection (n = 209, 34.2 %),
pleural effusion (n = 171, 28.0 %), fistula formation (n = 66,
10.8 %) and ileus (n = 69, 11.3 %). There was no significant
Table 2 Mortality and morbidity results of patients in group 1
and group 2
Group 1
(< 65 years old)
Group 2
(≥ 65 years old)
p
Total hospital stay (days)
median (range)
22.0 (5–306) 22.5 (6–157) 0.925
ICU stay (days) median
(range)
2.0 (0–71) 2.0 (1–101) 0.629
HDU stay (days) median
(range)
3.0 (0–39) 2.0 (0–39) 0.831
Hospital death n (%) 10 (2) 4 (3) 0.607
Complication grade n (%) 0.644
0 88 (18) 25 (20)
I 19 (4) 8 (6)
II 166 (34) 42 (34)
III 125 (26) 31 (25)
IV 89 (18) 18 (15)
Tumour-related OS median
(months) (95 % CI)
0.889
CRC (n = 184) 27.0 (20.4–33.6) 42.0 (30.1–53.3) 0.130
PMP (n = 157) MNR MNR 0.356
Mesothelioma (n = 53) 62.0 (17.2–106.8) 22.0 (5.5–38.5) 0.186
Appendiceal cancer (n=137) 64.0 (55.4–72.6) 43.0 (28.5–57.5) 0.475
Others (n = 80) 25.0 (16.8–33.2) 24.0 (4.8–43.2) 0.664
Table 3 Subgroup analysis: background characteristics and
clinical outcomes of patients who are 75 years of age or older






Age mean (range, SD) 76.7 (75–85)





CRC (n = 184) 5 (25.0)
PMP (n = 157) 6 (30.0)
Mesothelioma (n = 53) 2 (10.0)
Appendiceal cancer (n = 137) 6 (30.0)
Others (n = 80) 1 (5.0)
HIPEC n (%) 9 (45.0)
EPIC n (%) 5 (25.0)






Transfusion mean (SD) 5.2 (6.2)
Total hospital stay (days) median (range) 20.0 (9–157)
ICU stay (days) median (range) 2.0 (1–101)
HDU stay (days) median (range) 1.0 (0–20)
Hospital death n (%) 1 (5)






Tumour-related OS median (months) (95 %) 35.0 (17.3–52.7)
5-year OS (%) 18.6
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groups. (p = 0.644) (Table 2).
In terms of subgroup analysis, Table 3 summaries the
background characteristics and clinical outcomes of the
patients who were 75 years of age or older at the time of
surgery. The morbidity results of our subgroup were
similar to the results of patients who were less than
65 years old. However, the hospital mortality in the sub-
group was higher (5 % n = 1) than that of those who
were less than 65 years old (2 % n = 10) (Table 3).
Survival
Survival results were summarised in Table 2. Median
overall survival (OS) of patients who were less than
65 years old was 58.0 months (95 %CI = 47.0–68.9) with
a 5-year OS of 47.7 % whereas the elderly group had a
median OS of 43 months (95 %CI=38.1–47.9) with a 5-
year OS of 42.9 %. However, such a difference did not
reach a statistical significance (p = 0.698). Cox regression
analysis showed that age alone is not a prognostic factor
for survival of peritoneal carcinomatosis (p = 0.795).
The 5-year OS for patients with CRC was shown to be
26.8 %. The 10-year survival rate for patients with PMP
was 67.4 %. The overall 5-year OS for this group of
patients was 50.9 %. The overall 5-year OS for patients
with appendiceal cancer was 50.5 %. The overall 5-yearOS for patients with other types of cancers was 16.8 %
(Fig. 1).
In terms of subgroup analysis, the patients who were
75 years of age or older had a median OS of 35.0 months
(95 %CI = 17.3–52.7) with a 5-year OS of 18.6 %. Fur-
ther survival analysis based on tumour types was not
Fig. 1 Survival curves for two age groups
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diagnosis group.
Discussion
The Australian population is growing and ageing rapidly,
requiring more and more healthcare resources. The health
cost is expected to be doubled by 2051 as compared to
costs in 1996 [13]. Cancer-related surgery is expected to
rise substantially in the next few decades. According to
the Australian Bureau of Statistics, life expectancy
(additional years of life) of a male and a female reaching
65 is 18.7 and 21.8, respectively [14]. In the past, age
alone has been considered as a limiting factor for major
abdominal surgery. One previous study has shown that
elderly patients (those older than 70 years old) were at
higher risk of postoperative complications after non-
cardiac surgery [15]. Given the fact that CRS is per-
formed to remove all macroscopic disease, there are
usually extensive intra-abdominal areas involved. Mor-
bidity and mortality of CRC and PIC is not insignificant
[16]. Thus, shorter survival would have been expected
in the elderly patients. However, our study did not find
a significant survival difference between the elderly pa-
tients and the younger patients.
Our mortality rate for the elderly patients was similar to
the rate shown in the systemic review done by Chua et al.
[6]. They reviewed the morbidity and mortality outcomes
of CRS and HIPEC from all institutions and showed the
mortality rate ranged from 0.9–5.8 % in the tertiary cen-
tres. Mortality of the elderly patients in our study was 3 %,
which was not statistically different from the mortality of
the younger patients after undergoing CRS and PIC. Simi-
lar mortality and morbidity rates for performing CRS
and PIC for elderly patients as compared to younger pa-
tients have also been reported previously [7–9, 16, 17].
Although the mortality of our patients in the subgroup
(i.e. ≥75 years old) is higher than our overall mortality,
it is still consistent with the range of mortality reported
by Chua et al. [6]. Despite the differences in mortality,
the morbidity results of our subgroup are similar to the
results of patients who were less than 65 years old. In
terms of survival, the median OS and 5-year OS of the
patients in the subgroup are shorter than that of pa-
tients who were 65 years of age or older. However, it is
worth noting that the mean PCI in our subgroup was
much higher than that of patients who were less than
65 years old or those who were 65 years of age or older.
The lower rate of complete cytoreduction and higher
PCI may have contributed to the higher hospital mortal-
ity and the lower 5-year OS in patients who were
75 years of age or older. Also, the 5-year OS may not re-
flect the true survival of these patients in our subgroup
due to the fact that different cancer types could have
contributed differently to the OS. Unfortunately, wecould not perform survival analysis using tumour types
in our subgroup due to the limited number of patients
in each diagnosis group.
Several previous studies have assessed the safety of
CRS and HIPEC for the elderly patients. The most re-
cent study was done by Spiliotis et al., in which they
analysed the results of 100 patients and 30 of which
were over 70 years of age [7]. They suggested that it may
be safe to perform CRC and HIPEC for the elderly
population with a careful selection. An Italian study
done by Macri et al. presented a retrospective analysis of
30 patients who underwent CRS and HIPEC. They sug-
gested that a combination of CRS and HIPEC is suitable
for the elderly population by comparing patients aged
less than 65 years old against 11 patients aged older than
65 years old [9]. Also, Muller et al. [8] did a retrospect-
ive analysis of 44 patients over 65 and suggested that age
alone should not preclude patients from cytoreductive
surgery. However, they did not compare their results
against those who are 65 years of age or younger. Al-
though our findings are consistent with these studies, it
should be noted that suitability of our patients for CRS
and PIC was discussed during weekly peritonectomy
meetings. Only selected patients were offered this com-
bined therapy at our centre. Similar mortality, morbidity
and survival outcomes between our age groups may have
reflected the careful selection process. Thus, our find-
ings suggest that CRS combined with PIC can be safely
performed in the patients who are 65 years of age or
above with an acceptable mortality and morbidity after a
careful patient selection.
To our knowledge, our study is the largest study of pa-
tients over 65 years old in the literature. However, we
acknowledge that there were some limitations in this
study. This was a retrospective study conducted at a sin-
gle centre. There was undoubtedly selection bias during
the study. Also, clearly there will be a referral bias, and
we are not sure the number of elderly patients who were
not referred to our centre and turned down due to their
age alone. Moreover, our results were obtained in a
centre with an experience of more than 900 patients.
The learning curve and volume outcome effects in major
surgery and potentially peritonectomy may be potentially
important in this group of patients.
Conclusions
The balance between surgery-associated risks and poten-
tial benefits is always paramount. Our study suggests
that CRS and PIC can be safely performed for the elderly
patients. However, the decision to offer this combined
therapy is often complicated by other factors including
co-existing morbidities. Thus, CRS and PIC should only
be offered to a subset of elderly patients after careful se-
lection and discussion during a multidisciplinary team
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peritonectomy should also be considered since it further
complicates the availability of CRS and PIC to suitable
elderly patients. The healthcare cost of cytoreductive
surgery and HIPEC is acknowledged (on average be-
tween AUD$44,668 and AUD$92,308 depending on the
type of malignancy), and societal decisions need to be
made on its provision [17]. However, our results indicate
that in patients over 65 years old, good short- and long-
term results are achieved. Hence, age alone should not
be the single exclusion criterion but rather taken into
consideration along with other factors to determine the
suitability of elderly patients to undergo CRS and PIC.
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